Edison uses a focused ultrasound technique called histotripsy that destroys unwanted tissue at a subcellular level, the company said. Part of the agreement will include HistoSonics distributing Edison with Logiq E10; the Logiq platform will support planning, monitoring, and post-treatment assessment of liver therapy, according to the firm.

Edison is being tested in U.S. and European trials. HistoSonics secured breakthrough device designation for Edison for the histotripsy of liver tissue from the U.S. Food and Drug Administration in October 2021.